Decision

Early access to medicines scheme (EAMS) scientific opinion: pembrolizumab for non-small cell lung cancer

This publication was withdrawn on

Withdrawn as this product received a marketing authorisation from the European Commission.

EAMS scientific opinion given to pembrolizumab for metastatic non-small cell lung cancer (NSCLC), including the public assessment report.